Prescriber's Corner
Olaratumab: A New Strategy in the Treatment of Advanced Soft-Tissue Sarcoma
Donald C. Moore, PharmD, BCPS, BCOP, DPLA, and Lesli A. Lavery, PharmD, BCOP
Levine Cancer Institute, Atrium Health, Rock Hill, South Carolina; and Levine Cancer Institute, Atrium Health, Charlotte, North Carolina
Authors’ disclosures of conflicts of interest are found at the end of this article.
Donald C. Moore, PharmD, BCPS, BCOP, DPLA, Levine Cancer Institute, Atrium Health, 1656 Riverchase Blvd, Suite 1400, Rock Hill, SC 29732.
E-mail: donald.moore1@carolinashealthcare.org
J Adv Pract Oncol 2018;9(2):235–240 |
https://doi.org/10.6004/jadpro.2018.9.2.10 |
© 2018 Harborside™
ABSTRACT
Abstract
Olaratumab is a monoclonal antibody that recently received accelerated approval for the treatment of advanced soft-tissue sarcomas in combination with doxorubicin for a histologic subtype in which anthracycline-containing regimens is appropriate and disease is not amenable to curative surgery or radiotherapy. It inhibits platelet-derived growth factor receptor alpha, leading to the inhibition of tumor cell proliferation, angiogenesis, and metastasis. In a phase II clinical trial, olaratumab in combination with doxorubicin met its predefined primary endpoint of improving progression-free survival and secondary endpoint of overall survival compared to doxorubicin monotherapy in patients with advanced soft-tissue sarcoma. Common adverse events associated with the combination of olaratumab and doxorubicin include nausea, mucositis, neutropenia, and infusion-related reactions.
For access to the full length article, please
sign in.
